TrueMark Investments LLC Makes New Investment in Guardant Health, Inc. $GH

TrueMark Investments LLC acquired a new position in shares of Guardant Health, Inc. (NASDAQ:GH) in the 1st quarter, HoldingsChannel reports. The fund acquired 6,596 shares of the company’s stock, valued at approximately $609,000.

Other hedge funds have also made changes to their positions in the company. Erste Asset Management GmbH raised its position in shares of Guardant Health by 10.4% during the 3rd quarter. Erste Asset Management GmbH now owns 705,217 shares of the company’s stock worth $43,716,000 after acquiring an additional 66,617 shares in the last quarter. World Investment Advisors acquired a new position in Guardant Health in the fourth quarter valued at approximately $1,664,000. Segall Bryant & Hamill LLC boosted its holdings in Guardant Health by 57.8% in the third quarter. Segall Bryant & Hamill LLC now owns 305,147 shares of the company’s stock valued at $19,066,000 after purchasing an additional 111,822 shares in the last quarter. TD Asset Management Inc increased its stake in Guardant Health by 16.1% in the third quarter. TD Asset Management Inc now owns 188,810 shares of the company’s stock valued at $11,797,000 after purchasing an additional 26,210 shares during the last quarter. Finally, Algert Global LLC increased its stake in Guardant Health by 169.1% in the third quarter. Algert Global LLC now owns 120,114 shares of the company’s stock valued at $7,505,000 after purchasing an additional 75,474 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Buying and Selling at Guardant Health

In other news, insider John G. Saia sold 20,000 shares of Guardant Health stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $106.51, for a total value of $2,130,200.00. Following the transaction, the insider directly owned 45,950 shares of the company’s stock, valued at $4,894,134.50. The trade was a 30.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helmy Eltoukhy sold 100,000 shares of Guardant Health stock in a transaction on Friday, June 5th. The shares were sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the completion of the transaction, the chief executive officer directly owned 2,012,919 shares in the company, valued at $254,231,669.70. The trade was a 4.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 452,513 shares of company stock valued at $51,608,916. 5.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

GH has been the topic of a number of research analyst reports. UBS Group set a $150.00 price objective on shares of Guardant Health in a report on Wednesday. TD Cowen restated a “buy” rating on shares of Guardant Health in a report on Thursday, May 21st. Evercore raised shares of Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 target price on the stock in a research report on Tuesday, June 2nd. Piper Sandler set a $127.00 price target on shares of Guardant Health in a research note on Thursday, May 21st. Finally, Mizuho boosted their price target on shares of Guardant Health from $135.00 to $175.00 and gave the company an “outperform” rating in a research report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $142.19.

Guardant Health Stock Up 4.7%

GH opened at $136.96 on Thursday. Guardant Health, Inc. has a 52 week low of $40.35 and a 52 week high of $141.07. The business’s 50 day moving average is $110.21 and its two-hundred day moving average is $103.42. The firm has a market cap of $18.16 billion, a price-to-earnings ratio of -40.40 and a beta of 1.61.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.